Cargando…

Epidemiology and prediction model of patients with carcinosarcoma in the United States

BACKGROUND: Carcinosarcoma is a rare biphasic tumor composed of both carcinoma and sarcoma elements, which occurs at various sites. Most studies are case reports or small population-based studies for a single disease site, so comprehensive evaluations of epidemiology and prognostic factors for carci...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Mingjing, He, Xiandong, Yang, Qiao, Zhang, Jia, Peng, Jiayi, Wang, Danni, Tong, Kexin, Huang, Wenxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742429/
https://www.ncbi.nlm.nih.gov/pubmed/36518582
http://dx.doi.org/10.3389/fpubh.2022.1038211
_version_ 1784848515579510784
author Chen, Mingjing
He, Xiandong
Yang, Qiao
Zhang, Jia
Peng, Jiayi
Wang, Danni
Tong, Kexin
Huang, Wenxiang
author_facet Chen, Mingjing
He, Xiandong
Yang, Qiao
Zhang, Jia
Peng, Jiayi
Wang, Danni
Tong, Kexin
Huang, Wenxiang
author_sort Chen, Mingjing
collection PubMed
description BACKGROUND: Carcinosarcoma is a rare biphasic tumor composed of both carcinoma and sarcoma elements, which occurs at various sites. Most studies are case reports or small population-based studies for a single disease site, so comprehensive evaluations of epidemiology and prognostic factors for carcinosarcoma are needed. METHODS: Surveillance, Epidemiology, and End Results (SEER)-8 (1975–2019) provided data for the epidemiological analysis. SEER-17 (2000–2019) provided data on the primary tumor sites, initial treatment, construction, and validation of the nomogram. RESULTS: The age-adjusted incidence per 100,000 persons of carcinosarcoma increased significantly from 0.46 to 0.91 [1975–2019; average annual percent change (AAPC): 1.3%, P = 0.006], with localized stage increasing from 0.14 to 0.26 [2005–2015; annual percent change (APC): 4.2%]. The 20-year limited-duration prevalence per 100,000 increased from 0.47 to 3.36 (1999–2018). The mortality per 100,000 increased significantly from 0.16 to 0.51 (1975–2019; AAPC: 1.9%, P < 0.001). The 5-year relative survival was 32.8%. The greatest number of carcinosarcomas were from the uterus (68.7%), ovary (17.8%), lung and bronchus (2.3%). The main treatment is comprehensive treatment based on surgery; however, surgery alone is preferred in older patients. In multivariate analysis (N = 11,424), age, sex, race, year of diagnosis, disease stage, tumor site, and treatment were associated with survival. A nomogram was established to predict 1-, 3-, and 5-year survival, and the C-indexes were 0.732 and 0.748 for the training and testing sets, respectively. The receiver operating characteristic curve demonstrated that the nomogram provided a comprehensive and accurate prediction [1-year area under the curve (AUC): 0.782 vs. 0.796; 3-year AUC: 0.771 vs. 0.798; 5-year AUC: 0.777 vs. 0.810]. CONCLUSIONS: In this study, the incidence, prevalence, and mortality of carcinosarcoma have increased over the past decades. There was a rapid rise in the incidence of localized stage in recent years, which reflected improved early detection. The prognosis of carcinosarcoma remains poor, signifying the urgency of exploring targeted cancer control treatments. Explicating distribution and gender disparities of carcinosarcoma may facilitate disease screening and medical surveillance. The nomogram demonstrated good predictive capacity and facilitated clinical decision-making.
format Online
Article
Text
id pubmed-9742429
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97424292022-12-13 Epidemiology and prediction model of patients with carcinosarcoma in the United States Chen, Mingjing He, Xiandong Yang, Qiao Zhang, Jia Peng, Jiayi Wang, Danni Tong, Kexin Huang, Wenxiang Front Public Health Public Health BACKGROUND: Carcinosarcoma is a rare biphasic tumor composed of both carcinoma and sarcoma elements, which occurs at various sites. Most studies are case reports or small population-based studies for a single disease site, so comprehensive evaluations of epidemiology and prognostic factors for carcinosarcoma are needed. METHODS: Surveillance, Epidemiology, and End Results (SEER)-8 (1975–2019) provided data for the epidemiological analysis. SEER-17 (2000–2019) provided data on the primary tumor sites, initial treatment, construction, and validation of the nomogram. RESULTS: The age-adjusted incidence per 100,000 persons of carcinosarcoma increased significantly from 0.46 to 0.91 [1975–2019; average annual percent change (AAPC): 1.3%, P = 0.006], with localized stage increasing from 0.14 to 0.26 [2005–2015; annual percent change (APC): 4.2%]. The 20-year limited-duration prevalence per 100,000 increased from 0.47 to 3.36 (1999–2018). The mortality per 100,000 increased significantly from 0.16 to 0.51 (1975–2019; AAPC: 1.9%, P < 0.001). The 5-year relative survival was 32.8%. The greatest number of carcinosarcomas were from the uterus (68.7%), ovary (17.8%), lung and bronchus (2.3%). The main treatment is comprehensive treatment based on surgery; however, surgery alone is preferred in older patients. In multivariate analysis (N = 11,424), age, sex, race, year of diagnosis, disease stage, tumor site, and treatment were associated with survival. A nomogram was established to predict 1-, 3-, and 5-year survival, and the C-indexes were 0.732 and 0.748 for the training and testing sets, respectively. The receiver operating characteristic curve demonstrated that the nomogram provided a comprehensive and accurate prediction [1-year area under the curve (AUC): 0.782 vs. 0.796; 3-year AUC: 0.771 vs. 0.798; 5-year AUC: 0.777 vs. 0.810]. CONCLUSIONS: In this study, the incidence, prevalence, and mortality of carcinosarcoma have increased over the past decades. There was a rapid rise in the incidence of localized stage in recent years, which reflected improved early detection. The prognosis of carcinosarcoma remains poor, signifying the urgency of exploring targeted cancer control treatments. Explicating distribution and gender disparities of carcinosarcoma may facilitate disease screening and medical surveillance. The nomogram demonstrated good predictive capacity and facilitated clinical decision-making. Frontiers Media S.A. 2022-11-28 /pmc/articles/PMC9742429/ /pubmed/36518582 http://dx.doi.org/10.3389/fpubh.2022.1038211 Text en Copyright © 2022 Chen, He, Yang, Zhang, Peng, Wang, Tong and Huang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Chen, Mingjing
He, Xiandong
Yang, Qiao
Zhang, Jia
Peng, Jiayi
Wang, Danni
Tong, Kexin
Huang, Wenxiang
Epidemiology and prediction model of patients with carcinosarcoma in the United States
title Epidemiology and prediction model of patients with carcinosarcoma in the United States
title_full Epidemiology and prediction model of patients with carcinosarcoma in the United States
title_fullStr Epidemiology and prediction model of patients with carcinosarcoma in the United States
title_full_unstemmed Epidemiology and prediction model of patients with carcinosarcoma in the United States
title_short Epidemiology and prediction model of patients with carcinosarcoma in the United States
title_sort epidemiology and prediction model of patients with carcinosarcoma in the united states
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742429/
https://www.ncbi.nlm.nih.gov/pubmed/36518582
http://dx.doi.org/10.3389/fpubh.2022.1038211
work_keys_str_mv AT chenmingjing epidemiologyandpredictionmodelofpatientswithcarcinosarcomaintheunitedstates
AT hexiandong epidemiologyandpredictionmodelofpatientswithcarcinosarcomaintheunitedstates
AT yangqiao epidemiologyandpredictionmodelofpatientswithcarcinosarcomaintheunitedstates
AT zhangjia epidemiologyandpredictionmodelofpatientswithcarcinosarcomaintheunitedstates
AT pengjiayi epidemiologyandpredictionmodelofpatientswithcarcinosarcomaintheunitedstates
AT wangdanni epidemiologyandpredictionmodelofpatientswithcarcinosarcomaintheunitedstates
AT tongkexin epidemiologyandpredictionmodelofpatientswithcarcinosarcomaintheunitedstates
AT huangwenxiang epidemiologyandpredictionmodelofpatientswithcarcinosarcomaintheunitedstates